For asymptomatic people without known risks, the downsides and uncertainties of multi-cancer early detection testing could ...

Their makers claim they can detect dozens of cancer types — but some scientists say they could be missing many cancers or ...

Early detection tests are already on the market, but without FDA approval or proof they reduce deaths some doctors urge ...

For years, routine screening recommendations have been limited to four cancers — breast, cervical, colorectal, and high-risk lung cancer — leaving nearly 70% of annual cancer cases and ...

Shares in the company lost about half their value in Friday trading after the clinical trial failed to demonstrate a statistically significant reduction in stage III and IV cancers.

MADISON, Wis., September 10, 2025 — Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, today announced the launch of the Cancerguard™ test, a new multi-cancer early detection (MCED) ...

For patients facing a multiple myeloma diagnosis, the journey is often defined by a search for the next line of defense. For survivor Julie Cohen, that search led her to the front lines of medical ...

Clinical trial led by UAB researcher supports approval of new, potentially curative treatment for multiple myeloma ...